PDD Holdings Inc. American Depositary Shares vs uniQure N.V. Ordinary Shares — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $80.53 (market cap $116.66B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 78.8× uniQure N.V. Ordinary Shares's market cap, and PDD Holdings Inc. American Depositary Shares is more actively traded (9,095,378 versus 2,488,780). Which is the better fit depends on your goals.
| PDD | QURE | |
|---|---|---|
Market Cap | $116.66B | $1.48B |
Volume | 9,095,378 | 2,488,780 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $70.59 |
52-Week Low | $73.30 | $9.03 |
Enterprise Value | $49.19B | $728.62M |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
PDD Holdings trades at $81.96, up 1.29% with a bullish technical signal despite recent earnings volatility. The stock shows strong fundamentals with a P/E of 8.81 and robust profitability margins (net income margin 20.43%). Recent news highlights investor attention and the company's major investment cycle while facing regulatory and competitive pressures.
The outlook remains cautiously optimistic with a $99.13 consensus price target, though risks include trade policy impacts and execution challenges from PDD's shift to an asset-heavy model. Earnings misses in recent quarters and moderating revenue growth warrant close monitoring for sustained investor confidence.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →